MARKET

ATNFW

ATNFW

180 Life Sciences Corp.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
0.000
0.00%
Opening 12:00 07/23 EDT
OPEN
1.670
PREV CLOSE
1.650
HIGH
1.670
LOW
1.650
VOLUME
4.74K
TURNOVER
--
52 WEEK HIGH
2.970
52 WEEK LOW
0.1200
MARKET CAP
--
P/E (TTM)
-0.6351
1D
5D
1M
3M
1Y
5Y
BRIEF-180 Life Sciences Corp Files For Resale Of 5.44 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
reuters.com · 2d ago
180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 3d ago
BRIEF-180 Life Sciences Regains Nasdaq Compliance For Certain Listing Rules
reuters.com · 07/12 14:16
180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory d...
GlobeNewswire · 07/12 13:51
BRIEF-180 Life Sciences Corp Says Nasdaq Provided Written Notice To It That It Has Determined That Co Complies With Its Rules
reuters.com · 07/12 12:49
BRIEF-180 Life Sciences Expands Scientific Fibrosis Platform With Collagen Vi As A Driver And Disease Biomarker In Human Fibrosis Published In The Febs Journal
reuters.com · 07/07 12:13
180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal
PALO ALTO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 07/07 12:00
BRIEF-180 Life Sciences Joins Russell Microcap Index
reuters.com · 06/28 13:30
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNFW. Analyze the recent business situations of 180 Life Sciences Corp. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.26%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Chairman/Independent Director
George Hornig
Chief Executive Officer/Director
Marlene Krauss
Chief Operating Officer/Director
Joseph Williamson
Director
Larry Gold
Independent Director
Sherrill Neff
Independent Director
Andrew Sherman
No Data
About ATNFW
180 Life Sciences Corp., (180 Life Sciences) formerly KBL Merger Corp. IV., is a research and development company. The Company is focused on research into solving one of the diseases is inflammation. The Company consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.

Webull offers kinds of 180 Life Sciences Corp stock information, including NASDAQ:ATNFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNFW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNFW stock methods without spending real money on the virtual paper trading platform.